首页 > 最新文献

European Journal of Human Genetics最新文献

英文 中文
Systematic review of preferences for additional findings from genomic testing 对基因组检测的其他发现的偏好进行系统评价。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-20 DOI: 10.1038/s41431-025-01968-w
Daniel Sheen, Amanda Willis, Zoe Fehlberg, Melissa Southey, Ilias Goranitis, Mary-Anne Young
The increasing use of genomic testing in clinical and research contexts raises how best to manage additional findings (AFs). This systematic review of the preferences of clinical patients and research participants for what and how AFs should be returned, aims to inform development of guidelines and policies that are inclusive of test recipients. Framework analysis was used to systematically review qualitative and quantitative studies exploring preferences for AFs in clinical and research contexts and identify key themes. Eighty-seven studies were included involving a total of 71,486 study participants. The right to choose whether and what AFs to receive was highly supported. Actionable findings and findings with familial implications were highly desired across studies. Additionally, a substantial number of studies identified mixed interest in findings currently not returned, including non-actionable findings and variants of unknown significance (VUS). Penetrance and certainty influenced perceived relevance and decisions regarding what to receive, with varying thresholds identified within studies. This review identified a consistent desire for systematic support for test recipient decision-making and managing AFs. The findings of this review support existing emphasis on recipient choice. However, recipient strength of preference for a broad variety of findings indicates that a minimum acceptable return of actionable findings should be established in national guidelines and the feasibility of offering other types of findings should be explored.
在临床和研究中越来越多地使用基因组检测,提出了如何最好地管理附加发现(AFs)。本研究系统回顾了临床患者和研究参与者对AFs应退还的内容和方式的偏好,旨在为包括测试接受者在内的指导方针和政策的制定提供信息。框架分析用于系统地回顾定性和定量研究,探讨临床和研究背景下对AFs的偏好,并确定关键主题。87项研究共涉及71486名研究参与者。选择是否接受和接受何种AFs的权利得到了高度支持。可操作的发现和具有家族意义的发现在研究中是非常需要的。此外,大量的研究发现,目前尚未返回的发现,包括不可操作的发现和未知意义的变体(VUS)的混合兴趣。外显率和确定性影响感知的相关性和关于接受什么的决定,在研究中确定了不同的阈值。本综述确定了对测试接受者决策和管理AFs的系统支持的一致愿望。本综述的发现支持现有的对接受者选择的重视。但是,由于接受者对各种各样的调查结果的偏好程度表明,应在国家准则中确定可采取行动的调查结果的最低可接受回报,并应探讨提供其他类型调查结果的可行性。
{"title":"Systematic review of preferences for additional findings from genomic testing","authors":"Daniel Sheen, Amanda Willis, Zoe Fehlberg, Melissa Southey, Ilias Goranitis, Mary-Anne Young","doi":"10.1038/s41431-025-01968-w","DOIUrl":"10.1038/s41431-025-01968-w","url":null,"abstract":"The increasing use of genomic testing in clinical and research contexts raises how best to manage additional findings (AFs). This systematic review of the preferences of clinical patients and research participants for what and how AFs should be returned, aims to inform development of guidelines and policies that are inclusive of test recipients. Framework analysis was used to systematically review qualitative and quantitative studies exploring preferences for AFs in clinical and research contexts and identify key themes. Eighty-seven studies were included involving a total of 71,486 study participants. The right to choose whether and what AFs to receive was highly supported. Actionable findings and findings with familial implications were highly desired across studies. Additionally, a substantial number of studies identified mixed interest in findings currently not returned, including non-actionable findings and variants of unknown significance (VUS). Penetrance and certainty influenced perceived relevance and decisions regarding what to receive, with varying thresholds identified within studies. This review identified a consistent desire for systematic support for test recipient decision-making and managing AFs. The findings of this review support existing emphasis on recipient choice. However, recipient strength of preference for a broad variety of findings indicates that a minimum acceptable return of actionable findings should be established in national guidelines and the feasibility of offering other types of findings should be explored.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 1","pages":"10-26"},"PeriodicalIF":4.6,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01968-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endometriosis - on the intersection of modern environmental pollutants and ancient genetic regulatory variants 子宫内膜异位症-现代环境污染物和古代基因调控变异的交集。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-20 DOI: 10.1038/s41431-025-01977-9
Amelia Warren, Demetra Andreou, Dean Warren, Jack Wieland, Anna Mantzouratou
Endometriosis is a chronic, estrogen-driven inflammatory disorder affecting approximately 10% of reproductive-aged women globally. Despite increasing genomic insights into advanced-stage disease, the genetic underpinnings of early-stage endometriosis remain poorly understood, limiting opportunities for timely diagnosis and intervention. This study explores the contribution of regulatory variants, including those derived from ancient hominin introgression, and their interaction with modern environmental exposures in shaping endometriosis susceptibility. We conducted a dual-phase literature review to identify genes implicated in endometriosis pathophysiology and endocrine-disrupting chemical (EDC) sensitivity. Five genes (IL-6, CNR1, IDO1, TACR3, and KISS1R) were selected based on tissue expression, pathway involvement, and EDC reactivity. Whole-genome sequencing (WGS) data from the Genomics England 100,000 Genomes Project were analysed in nineteen females with clinically confirmed endometriosis. Variant enrichment, co-localisation, and linkage disequilibrium analyses were conducted, and functional impact was evaluated using public regulatory databases. Six regulatory variants were significantly enriched in the endometriosis cohort compared to matched controls and the general Genomics England population. Notably, co-localised IL-6 variants rs2069840 and rs34880821—located at a Neandertal-derived methylation site—demonstrated strong linkage disequilibrium and potential immune dysregulation. Variants in CNR1 and IDO1, some of Denisovan origin, also showed significant associations. Several of these variants overlapped EDC-responsive regulatory regions, suggesting gene-environment interactions may exacerbate risk. These findings propose a novel perspective of endometriosis susceptibility, in which ancient regulatory variants and contemporary environmental exposures converge to modulate immune and inflammatory responses. This integrative approach identified new potential biomarkers for early-stage detection of endometriosis.
子宫内膜异位症是一种慢性、雌激素驱动的炎症性疾病,影响全球约10%的育龄妇女。尽管对晚期疾病的基因组研究越来越深入,但早期子宫内膜异位症的遗传基础仍然知之甚少,这限制了及时诊断和干预的机会。本研究探讨了调节变异的贡献,包括那些源自古人类基因渗入的调节变异,以及它们与现代环境暴露在形成子宫内膜异位症易感性方面的相互作用。我们进行了两阶段的文献综述,以确定与子宫内膜异位症病理生理和内分泌干扰化学(EDC)敏感性有关的基因。5个基因(IL-6、CNR1、IDO1、TACR3和KISS1R)根据组织表达、通路参与和EDC反应性选择。来自英国基因组100000基因组计划的全基因组测序(WGS)数据分析了19名临床确诊子宫内膜异位症的女性。进行了变异富集、共定位和连锁不平衡分析,并使用公共监管数据库评估了功能影响。在子宫内膜异位症队列中,与匹配的对照组和英国通用基因组学人群相比,6个调节变异显著富集。值得注意的是,位于尼安德特人衍生甲基化位点的共定位IL-6变体rs2069840和rs34880821表现出强烈的连锁不平衡和潜在的免疫失调。来自丹尼索瓦人的CNR1和IDO1变异也显示出显著的相关性。其中一些变异与edc反应性调控区域重叠,表明基因与环境的相互作用可能加剧风险。这些发现提出了子宫内膜异位症易感性的新视角,其中古代的调节变异和当代的环境暴露共同调节免疫和炎症反应。这种综合方法确定了子宫内膜异位症早期检测的新的潜在生物标志物。
{"title":"Endometriosis - on the intersection of modern environmental pollutants and ancient genetic regulatory variants","authors":"Amelia Warren, Demetra Andreou, Dean Warren, Jack Wieland, Anna Mantzouratou","doi":"10.1038/s41431-025-01977-9","DOIUrl":"10.1038/s41431-025-01977-9","url":null,"abstract":"Endometriosis is a chronic, estrogen-driven inflammatory disorder affecting approximately 10% of reproductive-aged women globally. Despite increasing genomic insights into advanced-stage disease, the genetic underpinnings of early-stage endometriosis remain poorly understood, limiting opportunities for timely diagnosis and intervention. This study explores the contribution of regulatory variants, including those derived from ancient hominin introgression, and their interaction with modern environmental exposures in shaping endometriosis susceptibility. We conducted a dual-phase literature review to identify genes implicated in endometriosis pathophysiology and endocrine-disrupting chemical (EDC) sensitivity. Five genes (IL-6, CNR1, IDO1, TACR3, and KISS1R) were selected based on tissue expression, pathway involvement, and EDC reactivity. Whole-genome sequencing (WGS) data from the Genomics England 100,000 Genomes Project were analysed in nineteen females with clinically confirmed endometriosis. Variant enrichment, co-localisation, and linkage disequilibrium analyses were conducted, and functional impact was evaluated using public regulatory databases. Six regulatory variants were significantly enriched in the endometriosis cohort compared to matched controls and the general Genomics England population. Notably, co-localised IL-6 variants rs2069840 and rs34880821—located at a Neandertal-derived methylation site—demonstrated strong linkage disequilibrium and potential immune dysregulation. Variants in CNR1 and IDO1, some of Denisovan origin, also showed significant associations. Several of these variants overlapped EDC-responsive regulatory regions, suggesting gene-environment interactions may exacerbate risk. These findings propose a novel perspective of endometriosis susceptibility, in which ancient regulatory variants and contemporary environmental exposures converge to modulate immune and inflammatory responses. This integrative approach identified new potential biomarkers for early-stage detection of endometriosis.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 2","pages":"243-251"},"PeriodicalIF":4.6,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01977-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community 在一般实践中加强家族性高胆固醇血症的检测:支持社区基因级联检测的模型。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-17 DOI: 10.1038/s41431-025-01979-7
Jing Pang, Wendy Barnett, Jane Purdie, Jennifer A. Della-Vedova, Annmarie Woodward, Damon A. Bell, Amanda J. Hooper, Dick C. Chan, Andrew C. Martin, Kristen J. Nowak, Jacquie Garton-Smith, Gerald F. Watts
Familial hypercholesterolaemia (FH) is a common, co-dominant cause of premature coronary artery disease that remains under-recognised worldwide. Genetic testing, the most accurate diagnostic method, is particularly valuable in the cascade testing of close blood relatives, but there is little experience in general practice. We developed a tertiary-primary shared care model to identify genetic FH among first-degree relatives (FDRs) of FH index cases. Service and clinical outcomes were assessed. From a total of 153 FDRs of 90 adult FH index cases, 105 (corresponding to 64 index cases) undertook genetic testing by their general practitioner (GP). Median age of the FDRs was 14.8 years (range 3–79 years), 54% being male, 80% Caucasian, 61% children/adolescents, and 80% progeny. The number of new FDRs with a pathogenic variant per index case was 0.89 (95% CI, 0.69–1.10), with an uptake and yield of testing of 95% and 50%, respectively. Relatives with a pathogenic variant had significantly higher LDL-cholesterol than those without (5.9 ± 1.8 vs. 2.7 ± 0.9 mmol/L, p < 0.001). Among 31 relatives initiated on treatment after a genetic diagnosis, a 46% reduction in LDL-cholesterol was achieved with 45% attaining guideline-directed goals. Genetic cascade testing of FDRs of index cases with FH is feasible and effective in a shared-care model in which GPs are supported by a tertiary centre. These preliminary findings inform the development of centralised and sustained models of care, with implications for the detection of FH in communities.
家族性高胆固醇血症(FH)是一种常见的、共同主导的过早冠状动脉疾病的原因,在世界范围内仍未得到充分认识。基因检测是最准确的诊断方法,在近亲的级联检测中特别有价值,但在一般实践中缺乏经验。我们开发了一个三级-初级共同护理模型,以确定FH指数病例的一级亲属(fdr)的遗传性FH。评估服务和临床结果。在90名成人FH指数病例的153名fdr中,105名(相当于64名指数病例)接受了全科医生的基因检测。fdr的中位年龄为14.8岁(范围3-79岁),54%为男性,80%为白种人,61%为儿童/青少年,80%为后代。每个指数病例中带有致病变异的新fdr数为0.89 (95% CI, 0.69-1.10),检测的吸收率和产率分别为95%和50%。有致病变异的亲属ldl -胆固醇明显高于无致病变异的亲属(5.9±1.8 vs. 2.7±0.9 mmol/L, p
{"title":"Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community","authors":"Jing Pang,&nbsp;Wendy Barnett,&nbsp;Jane Purdie,&nbsp;Jennifer A. Della-Vedova,&nbsp;Annmarie Woodward,&nbsp;Damon A. Bell,&nbsp;Amanda J. Hooper,&nbsp;Dick C. Chan,&nbsp;Andrew C. Martin,&nbsp;Kristen J. Nowak,&nbsp;Jacquie Garton-Smith,&nbsp;Gerald F. Watts","doi":"10.1038/s41431-025-01979-7","DOIUrl":"10.1038/s41431-025-01979-7","url":null,"abstract":"Familial hypercholesterolaemia (FH) is a common, co-dominant cause of premature coronary artery disease that remains under-recognised worldwide. Genetic testing, the most accurate diagnostic method, is particularly valuable in the cascade testing of close blood relatives, but there is little experience in general practice. We developed a tertiary-primary shared care model to identify genetic FH among first-degree relatives (FDRs) of FH index cases. Service and clinical outcomes were assessed. From a total of 153 FDRs of 90 adult FH index cases, 105 (corresponding to 64 index cases) undertook genetic testing by their general practitioner (GP). Median age of the FDRs was 14.8 years (range 3–79 years), 54% being male, 80% Caucasian, 61% children/adolescents, and 80% progeny. The number of new FDRs with a pathogenic variant per index case was 0.89 (95% CI, 0.69–1.10), with an uptake and yield of testing of 95% and 50%, respectively. Relatives with a pathogenic variant had significantly higher LDL-cholesterol than those without (5.9 ± 1.8 vs. 2.7 ± 0.9 mmol/L, p &lt; 0.001). Among 31 relatives initiated on treatment after a genetic diagnosis, a 46% reduction in LDL-cholesterol was achieved with 45% attaining guideline-directed goals. Genetic cascade testing of FDRs of index cases with FH is feasible and effective in a shared-care model in which GPs are supported by a tertiary centre. These preliminary findings inform the development of centralised and sustained models of care, with implications for the detection of FH in communities.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 2","pages":"252-259"},"PeriodicalIF":4.6,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brugada Syndrome: an exemplar for the genomic basis of sudden death. Brugada综合征:猝死基因组基础的一个范例。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-14 DOI: 10.1038/s41431-025-01972-0
Rebecca L M Griffiths, Roddy Walsh, Marta Futema, Mark Specterman, Elijah R Behr

The inherited arrhythmia syndrome, Brugada Syndrome (BrS), is a leading cause of autopsy negative sudden death: the sudden arrhythmic death syndrome. Historically, BrS was believed to exhibit a Mendelian (autosomal dominant) mode of inheritance, caused by rare variants in SCN5A, the gene coding for the alpha subunit of the main cardiac sodium voltage channel. Challenges to this paradigm have arisen. For example, the majority of BrS cases do not exhibit rare variants in SCN5A. Moreover, genotype-phenotype mismatch in families has been observed. These findings suggest a more complex genetic architecture underpinning BrS. Subsequent large genomic studies of international patient cohorts have shown an unexpectedly high contribution of common genetic variation to its phenotypic development and severity. This has led to an alternative disease hypothesis whereby BrS develops as result of accumulated genetic and environmental risk surpassing a 'disease threshold' - the higher the accumulated risk, the more severe the clinical phenotype. Whilst expansion of standard clinical genetic testing to include an assessment of common variation might assist with diagnosis and phenotypic severity prediction in BrS, its incorporation into clinical practice presents inherent challenges which require careful consideration.

遗传性心律失常综合征,Brugada综合征(BrS),是尸检阴性猝死的主要原因:突发性心律失常死亡综合征。从历史上看,BrS被认为表现出孟德尔(常染色体显性)遗传模式,由SCN5A的罕见变异引起,SCN5A是编码心脏钠主电压通道α亚基的基因。对这一范式的挑战已经出现。例如,大多数BrS病例在SCN5A中不表现出罕见的变异。此外,还观察到家族中基因型-表型不匹配。这些发现表明,支持BrS的遗传结构更为复杂。随后对国际患者队列进行的大型基因组研究显示,共同遗传变异对其表型发展和严重程度的贡献出乎意料地高。这导致了另一种疾病假说,即BrS的发展是累积的遗传和环境风险超过“疾病阈值”的结果——累积的风险越高,临床表型就越严重。虽然将标准临床基因检测扩展到包括对常见变异的评估可能有助于BrS的诊断和表型严重程度预测,但将其纳入临床实践存在固有的挑战,需要仔细考虑。
{"title":"Brugada Syndrome: an exemplar for the genomic basis of sudden death.","authors":"Rebecca L M Griffiths, Roddy Walsh, Marta Futema, Mark Specterman, Elijah R Behr","doi":"10.1038/s41431-025-01972-0","DOIUrl":"https://doi.org/10.1038/s41431-025-01972-0","url":null,"abstract":"<p><p>The inherited arrhythmia syndrome, Brugada Syndrome (BrS), is a leading cause of autopsy negative sudden death: the sudden arrhythmic death syndrome. Historically, BrS was believed to exhibit a Mendelian (autosomal dominant) mode of inheritance, caused by rare variants in SCN5A, the gene coding for the alpha subunit of the main cardiac sodium voltage channel. Challenges to this paradigm have arisen. For example, the majority of BrS cases do not exhibit rare variants in SCN5A. Moreover, genotype-phenotype mismatch in families has been observed. These findings suggest a more complex genetic architecture underpinning BrS. Subsequent large genomic studies of international patient cohorts have shown an unexpectedly high contribution of common genetic variation to its phenotypic development and severity. This has led to an alternative disease hypothesis whereby BrS develops as result of accumulated genetic and environmental risk surpassing a 'disease threshold' - the higher the accumulated risk, the more severe the clinical phenotype. Whilst expansion of standard clinical genetic testing to include an assessment of common variation might assist with diagnosis and phenotypic severity prediction in BrS, its incorporation into clinical practice presents inherent challenges which require careful consideration.</p>","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145523281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of genetic counselling for familial colorectal cancer. A randomised clinical trial 家族性结直肠癌遗传咨询的疗效分析。一项随机临床试验。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-07 DOI: 10.1038/s41431-025-01921-x
Andrada Ciucă, Tara Clancy, Sebastian Pintea, Ramona Moldovan
Genetic counselling (GC) for familial colorectal cancer (fCRC) has been previously shown to improve outcomes such as emotional distress and screening adherence. This is the first randomised clinical trial to evaluate the efficacy of GC for fCRC. We included individuals affected or at-risk for fCRC (Lynch syndrome, APC-associated polyposis, other risk-associated pathogenic variants and clinically defined fCRC). Participants were randomised to (1) standard care or (2) standard care and genetic counselling. Measures include empowerment, anxiety, depression, knowledge, emotional distress, perceived social support, risk perception. Eighty-two individuals participated in the study. The average age was 44.81 years old, with 52.4% women. There was a significant effect in the counselling group (42/82) on post-intervention empowerment scores compared to the control group (40/82) (p = 0.004, d = 0.71), and similarly for depression (p = 0.025, d = 0.40), anxiety (p = 0.036, d = 0.35) and knowledge (p = 0.016, d = 0.25). Exploratory analysis show that several sociodemographic, affective and cognitive variables are moderating the improvement in empowerment following genetic counselling. Our data show significant improvements for both primary endpoint (empowerment) and secondary endpoints (knowledge, depression, anxiety, emotional distress). Genetic counselling is an effective intervention for fCRC both when the diagnosis is part of a syndrome or clinically defined, and both for affected or at-risk individuals.
家族性结直肠癌(fCRC)的遗传咨询(GC)先前已被证明可以改善情绪困扰和筛查依从性等结果。这是首个评估GC治疗fCRC疗效的随机临床试验。我们纳入了受fCRC影响或有fCRC风险的个体(Lynch综合征、apc相关息肉病、其他风险相关致病变异和临床定义的fCRC)。参与者被随机分配到(1)标准治疗组或(2)标准治疗和遗传咨询组。衡量标准包括赋权、焦虑、抑郁、知识、情绪困扰、感知社会支持、风险感知。82个人参与了这项研究。平均年龄44.81岁,女性占52.4%。辅导组(42/82)干预后赋权得分与对照组(40/82)比较差异有统计学意义(p = 0.004, d = 0.71),抑郁(p = 0.025, d = 0.40)、焦虑(p = 0.036, d = 0.35)、知识(p = 0.016, d = 0.25)得分差异有统计学意义(p = 0.036, d = 0.35)。探索性分析表明,一些社会人口、情感和认知变量正在调节遗传咨询后赋权的改善。我们的数据显示,主要终点(赋权)和次要终点(知识、抑郁、焦虑、情绪困扰)均有显著改善。遗传咨询对于fCRC是一种有效的干预手段,无论是当诊断为综合征的一部分或临床定义时,还是对于受影响或有风险的个体。
{"title":"The efficacy of genetic counselling for familial colorectal cancer. A randomised clinical trial","authors":"Andrada Ciucă,&nbsp;Tara Clancy,&nbsp;Sebastian Pintea,&nbsp;Ramona Moldovan","doi":"10.1038/s41431-025-01921-x","DOIUrl":"10.1038/s41431-025-01921-x","url":null,"abstract":"Genetic counselling (GC) for familial colorectal cancer (fCRC) has been previously shown to improve outcomes such as emotional distress and screening adherence. This is the first randomised clinical trial to evaluate the efficacy of GC for fCRC. We included individuals affected or at-risk for fCRC (Lynch syndrome, APC-associated polyposis, other risk-associated pathogenic variants and clinically defined fCRC). Participants were randomised to (1) standard care or (2) standard care and genetic counselling. Measures include empowerment, anxiety, depression, knowledge, emotional distress, perceived social support, risk perception. Eighty-two individuals participated in the study. The average age was 44.81 years old, with 52.4% women. There was a significant effect in the counselling group (42/82) on post-intervention empowerment scores compared to the control group (40/82) (p = 0.004, d = 0.71), and similarly for depression (p = 0.025, d = 0.40), anxiety (p = 0.036, d = 0.35) and knowledge (p = 0.016, d = 0.25). Exploratory analysis show that several sociodemographic, affective and cognitive variables are moderating the improvement in empowerment following genetic counselling. Our data show significant improvements for both primary endpoint (empowerment) and secondary endpoints (knowledge, depression, anxiety, emotional distress). Genetic counselling is an effective intervention for fCRC both when the diagnosis is part of a syndrome or clinically defined, and both for affected or at-risk individuals.","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"34 1","pages":"70-77"},"PeriodicalIF":4.6,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01921-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145470876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing towards clear and patient-centred language in cancer genetics. 癌症遗传学向着清晰和以患者为中心的语言迈进。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-05 DOI: 10.1038/s41431-025-01976-w
Saar Van Pottelberghe, Frederik J Hes, Maurizio Genuardi

Language in clinical genetics is never neutral. The terms used to describe genetic concepts, like mutation or variant, sporadic or hereditary, patient or counselee not only shape scientific discourse but also profoundly affect how individuals understand their risks, experience counselling, and make decisions. Terminology carries ethical weight, influencing perceptions of identity, stigma, and inclusion. Precision and empathy in language are therefore central to ethical and effective care. We propose the use of consistent terminology in communication that integrates three ethical responsibilities, promoting inclusivity through careful terminology, fostering psychosocial awareness by recognising that words can evoke fear or stigma, or offer reassurance and communicative clarity. This can be achieved by standardising professional terminology (e.g., variant, sporadic/hereditary) while co-constructing meaning with counselees. We recommend avoiding ambiguous labels like positive or negative, using precise qualifiers for variants and harmonising language across professional disciplines. Communication itself can be a clinical intervention, as careful paraphrasing and clarification both enhance understanding and provide emotional support. As genetic testing becomes increasingly mainstream in oncology, empathetic, precise, and patient-centred communication is essential. By fostering clarity and reducing stigma, language can support informed decision-making, trust, and ultimately, the ethical integration of genetics into everyday healthcare.

临床遗传学的语言从来不是中立的。用于描述基因概念的术语,如突变或变异,零星或遗传,患者或咨询者,不仅塑造了科学话语,而且深刻影响了个人如何理解他们的风险,经历咨询和做出决定。术语具有伦理意义,影响身份、污名和包容的观念。因此,语言的精确性和同理心是道德和有效护理的核心。我们建议在沟通中使用统一的术语,整合三种道德责任,通过谨慎的术语促进包容性,通过认识到词语可能引起恐惧或耻辱来培养社会心理意识,或提供安慰和沟通清晰度。这可以通过标准化专业术语(例如,变体,零星/遗传)来实现,同时与咨询师共同构建意义。我们建议避免模棱两可的标签,如肯定或否定,使用精确的限定词的变体和协调跨专业学科的语言。沟通本身可以是一种临床干预,因为仔细的解释和澄清既能增进理解,又能提供情感支持。随着基因检测在肿瘤学领域日益成为主流,同理心、精确和以患者为中心的沟通是必不可少的。通过提高清晰度和减少耻辱感,语言可以支持明智的决策、信任,并最终将遗传学纳入日常医疗保健。
{"title":"Advancing towards clear and patient-centred language in cancer genetics.","authors":"Saar Van Pottelberghe, Frederik J Hes, Maurizio Genuardi","doi":"10.1038/s41431-025-01976-w","DOIUrl":"https://doi.org/10.1038/s41431-025-01976-w","url":null,"abstract":"<p><p>Language in clinical genetics is never neutral. The terms used to describe genetic concepts, like mutation or variant, sporadic or hereditary, patient or counselee not only shape scientific discourse but also profoundly affect how individuals understand their risks, experience counselling, and make decisions. Terminology carries ethical weight, influencing perceptions of identity, stigma, and inclusion. Precision and empathy in language are therefore central to ethical and effective care. We propose the use of consistent terminology in communication that integrates three ethical responsibilities, promoting inclusivity through careful terminology, fostering psychosocial awareness by recognising that words can evoke fear or stigma, or offer reassurance and communicative clarity. This can be achieved by standardising professional terminology (e.g., variant, sporadic/hereditary) while co-constructing meaning with counselees. We recommend avoiding ambiguous labels like positive or negative, using precise qualifiers for variants and harmonising language across professional disciplines. Communication itself can be a clinical intervention, as careful paraphrasing and clarification both enhance understanding and provide emotional support. As genetic testing becomes increasingly mainstream in oncology, empathetic, precise, and patient-centred communication is essential. By fostering clarity and reducing stigma, language can support informed decision-making, trust, and ultimately, the ethical integration of genetics into everyday healthcare.</p>","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on the LMSz method: a novel approach to gene-specific growth charts for rare neurodevelopmental disorders. LMSz方法:罕见神经发育障碍基因特异性生长图的新方法。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-03 DOI: 10.1038/s41431-025-01975-x
Gyaneshwer Chaubey
{"title":"Commentary on the LMSz method: a novel approach to gene-specific growth charts for rare neurodevelopmental disorders.","authors":"Gyaneshwer Chaubey","doi":"10.1038/s41431-025-01975-x","DOIUrl":"10.1038/s41431-025-01975-x","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights in genetics: from molecular mechanisms to patient perspectives 遗传学的见解:从分子机制到患者的观点
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-03 DOI: 10.1038/s41431-025-01970-2
Seda S. Zonuzi
{"title":"Insights in genetics: from molecular mechanisms to patient perspectives","authors":"Seda S. Zonuzi","doi":"10.1038/s41431-025-01970-2","DOIUrl":"10.1038/s41431-025-01970-2","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 11","pages":"1387-1388"},"PeriodicalIF":4.6,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41431-025-01970-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference: ePosters. 第58届欧洲人类遗传学学会(ESHG)会议摘要:电子海报。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01934-6
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference: ePosters.","authors":"","doi":"10.1038/s41431-025-01934-6","DOIUrl":"10.1038/s41431-025-01934-6","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"110-507"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts from the 58th European Society of Human Genetics (ESHG) Conference: Hybrid Posters. 第58届欧洲人类遗传学学会(ESHG)会议:杂交海报摘要。
IF 4.6 2区 生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2025-11-01 DOI: 10.1038/s41431-025-01935-5
{"title":"Abstracts from the 58<sup>th</sup> European Society of Human Genetics (ESHG) Conference: Hybrid Posters.","authors":"","doi":"10.1038/s41431-025-01935-5","DOIUrl":"10.1038/s41431-025-01935-5","url":null,"abstract":"","PeriodicalId":12016,"journal":{"name":"European Journal of Human Genetics","volume":"33 Suppl 1","pages":"508-1220"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Human Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1